BMJ:产前使用糖皮质激素,可以降低足月儿、晚期早产儿的呼吸系统疾病风险

2016-10-13 MedSci MedSci原创

本项荟萃分析旨在评估妊娠≥34周后、产前予以糖皮质激素,对足月儿(≥37周)或晚期早产儿(34周到<37周)的影响。主要结果为严重的呼吸窘迫综合征(RDS)的发生率。 荟萃分析共纳入了6项试验,涉及5698例单胎妊娠;3项纳入了3200例入院时为妊娠34周到<37周、有早产风险的孕妇;其余3项纳入了2498例孕妇,在妊娠≥37周时进行计划性剖宫产手术。 总的来说,与对照组相比,妊娠≥3

本项荟萃分析旨在评估妊娠≥34周后、产前予以糖皮质激素,对足月儿(≥37周)或晚期早产儿(34周到<37周)的影响。主要结果为严重的呼吸窘迫综合征(RDS)的发生率。

荟萃分析共纳入了6项试验,涉及5698例单胎妊娠;3项纳入了3200例入院时为妊娠34周到<37周、有早产风险的孕妇;其余3项纳入了2498例孕妇,在妊娠≥37周时进行计划性剖宫产手术。

总的来说,与对照组相比,妊娠≥34周后、产前予以糖皮质激素的婴儿,RDS风险更低(RR0.74, 95% CI 0.61 to 0.91),轻度RDS风险更低(0.67, 0.46 to 0.96),中度RDS风险更低(0.39, 0.18 to 0.89),新生儿湿肺风险更低(0.56, 0.37 to 0.86),重度RDS风险更低(0.55, 0.33 to 0.91),使用表面活性剂、机械通气和吸氧时间更低(平均差 −2.06小时,95% CI  −2.17 to −1.95),最大吸入氧浓度更低(−0.66%, −0.69% to −0.63%),新生儿ICU住院时间更短(−7.64天,−7.65−7.64),Apgar评分更高。

对于妊娠34周到<37周出生的早产儿,以下风险更低:新生儿暂时性呼吸急促(RR 0.72, 95% CI 0.56 to 0.92)、重度RDS(0.60, 0.33 to 0.94)、使用表面活性剂(0.61, 0.38 to 0.99)。

对于≥37周、计划性剖宫产出生的婴儿,分娩前48小时使用糖皮质激素,以下风险更低:RDS(0.40, 0.27 to 0.59)、轻度RDS(0.43, 0.26 to 0.72)、中度RDS(0.40, 0.18 to 0.88)、新生儿湿肺(0.38, 0.25 to 0.57)、机械通气(0.19, 0.08 to 0.43)、吸氧时间更短(平均差  −2.06小时,95% CI −2.17 to −1.95)、最大吸入氧浓度百分比更低(−0.66%, −0.69% to −0.63%)、新生儿ICU住院时间更短(−7.44天,−7.44−7.43)、产后5分钟Apgar评分更高。

荟萃分析结果表明,妊娠≥34周后、产前予以糖皮质激素,可以减少新生儿呼吸系统疾病。尤其是对于妊娠34周到<37周、有早产风险的孕妇,以及妊娠≥37周时进行计划性剖宫产手术的孕妇。

原始出处:


Gabriele Saccone,et al.Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials.BMJ 2016;355:i5044

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2017-06-20 仁心济世
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2016-10-16 yongyuanaiping

    不好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2016-10-15 qilu_qi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2016-10-15 yongyuanaiping

    仔细看,漏洞也很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2016-10-15 1de8ed50m80(暂无匿称)

    学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1848123, encodeId=2dd5184812337, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jun 20 04:38:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701148, encodeId=e31c1e01148e5, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 16 00:38:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148825, encodeId=09fc14882548, content=不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sun Oct 16 15:36:40 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600253, encodeId=d354160025355, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502490, encodeId=46cd15024906a, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473028, encodeId=58e214e30286a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419001, encodeId=381414190011c, content=<a href='/topic/show?id=ab4d3969143' target=_blank style='color:#2F92EE;'>#呼吸系统疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39691, encryptionId=ab4d3969143, topicName=呼吸系统疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75de3457664, createdName=医生2395, createdTime=Sat Oct 15 13:38:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148519, encodeId=b5e1148519b6, content=仔细看,漏洞也很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Sat Oct 15 09:58:59 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148426, encodeId=09bc14842610, content=学习了,目前大多数还是34周以后不用糖皮质激素的,期待以后有新的研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Sat Oct 15 06:37:17 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148415, encodeId=5cef148415a6, content=学了下,真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Oct 15 05:46:14 CST 2016, time=2016-10-15, status=1, ipAttribution=)]
    2016-10-15 圣艮山

    学了下,真不错

    0

相关资讯

J Clin Endocrinol Metab:库欣综合征的血管损害是可逆的?

Cushing综合征是肾上腺皮质分泌过量的糖皮质激素(主要是皮质醇)所致。主要临床表现为满月脸、多血质、向心性肥胖、皮肤紫纹、痤疮、高血压和骨质疏松等。活跃库欣综合征(CS)患者经历内皮功能障碍和过早动脉粥样硬化;不过长期缓解后血管健康能恢复到什么程度是不清楚的,而这一方面又于未来心血管疾病的发展密切相关。因此研究者对没有合并症或适当治疗合并症的患者进行了横断面病例对照研究,调查CS长期缓解后,微

J Arthroplasty:围手术期使用糖皮质激素影对一些标志物的影响研究

手术会导致白细胞介素6(IL-6)的迅速上升,可能会增加深静脉血栓形成和医疗并发症的风险。进行全膝关节置换术的患者在围手术期应用糖皮质激素能抑制IL-6的释放。本研究评估围手术期应用糖皮质激素对IL-6的形成、血栓形成、纤维蛋白溶解和单侧非骨水泥型全髋关节置换术患者临床结局的影响。 在这项随机、双盲、安慰剂对照试验中,纳入了27名患者,14名安慰机组,13名为研究组。研究组患者给予泼尼松口服

安进Prolia治疗糖皮质激素诱导性骨质疏松症(GIOP) III期获得成功

美国生物技术巨头安进(Amgen)近日公布了骨质疏松症药物Prolia(denosumab,狄诺塞麦)一项III期临床研究GIOP(糖皮质激素诱导性骨质疏松症)的积极顶线数据。该研究是一项随机、双盲、双模拟、主动控制研究,在正接受糖皮质激素(glucocorticoid)治疗的患者中开展,评估了Prolia相对于利塞磷酸钠(risedronate)的疗效和安全性。研究中,患者接受利塞磷酸钠或Pro

低剂量糖皮质激素可降低严重烧伤患者并发症发生率

过度全身炎症反应是严重烧伤后一个尚未解决的重要问题。本研究旨在评价低剂量糖皮质激素治疗在下调严重烧伤患者全身炎症反应中的作用。研究共纳入69例70%TBSA及以上面积烧伤患者,其中31例急性期应用低剂量糖皮质激素治疗作为试验组,其余38例未接受前述激素治疗作为对照组。比较2组患者血浆炎症因子水平及临床转归。结果显示,试验组患者肺部感染、应激性溃疡和/或出血的发生率分别为24.2%、3.0%,明显低

J Am Acad Dermatol:特应性皮炎:钙调磷酸酶抑制剂 vs 糖皮质激素

目的:钙调磷酸酶抑制剂是过敏性皮炎的皮质类固醇治疗的替代品。我们试图比较与这些疗法在治疗特应性皮炎患者上的有益效果和不良事件。方法:四数据库中搜索比较外用钙调磷酸酶抑制剂和皮质类固醇激素对儿童和成人特应性皮炎的有效性和安全性的随机临床试验。结果:12个独立的随机临床试验比较了钙调神经磷酸酶抑制剂(n = 3492)与糖皮质激素(n = 3462)。数据显示,钙调磷酸酶抑制剂和糖皮质激素治疗的患者改

盘点:糖皮质激素到底是天使还是魔鬼?

糖皮质激素(glucocorticoid,GC)在生理状态下是维持机体正常物质代谢所必需的一种甾体类激素,在超生理量的糖皮质激素,具有强大的抗炎作用、抗过敏、非特异性抑制免疫及退热作用等多种药理作用,是一类临床适应证尤其是相对适应证较广的药物。但是,临床应用的随意性较大,若使用不规范各种副作用层出不穷,造成疾病变得复杂、病程延长、患者谈激素色变等现象。梅斯医学小编盘点了近期有关糖皮质激素的最新